Abstract: Compounds of formula I ##STR1## in which R.sub.1 is a heterocyclic ring containing one or more heteroatoms selected from N, O and S;in which R.sub.2 is H, a straight or branched chain alkyl group containing 1 to 4 carbon atoms, an alkenyl group containing 3 to 6 carbon atoms, an alkynyl group containing 3 to 6 carbon atoms or a cycloalkyl group containing 3 to 7 carbon atoms;in which R.sub.3, is H, a straight chain alkyl group containing 1 to 3 carbon atoms or a formyl groupin which R.sub.4, R.sub.5 and R.sub.6 which may be the same or different, are H, halo, trifluoromethyl, hydroxy, an alkyl group containing 1 to 3 carbon atoms, an alkoxy group containing 1 to 3 carbon atoms, phenyl or R.sub.4 and R.sub.5, together with the carbon atoms to which they are attached, form an optionally substituted second benzene ring;and their pharmaceutically acceptable salts have utility in the treatment of depression. Pharmaceutical compositions and processes for the preparation of compounds of formula I are disclosed.

Abstract: A pharmaceutical composition for oral administration comprising a mixture of ibuprofen or a pharmaceutically acceptable salt thereof and aluminium hydroxide, the amount of aluminium hydroxide being sufficient to mask the bitter taste of the ibuprofen, or the salt thereof which would be evident in the absence of aluminium hydroxide.The ratio of aluminium hydroxide (expressed as equivalent aluminium oxide) to ibuprofen may be in the range 1:50 to 5:1 parts by weight.

Abstract: Novel solid antibacterial compositions suitable for use in an oil or gas well comprise at least 50% by weight of a solid antibacterial nitroalkanol compound active against sulphate-reducing bacteria and a carrier, the composition having a density of at least 1.2 g/cm.sup.3 and being adapted to dissolve, disintegrate or disperse in water but not in oil. A preferred antimicrobial compound is 2-bromo-2-nitropropane-1,3-diol. The antibacterial compositions are introduced into the aqueous layer in the sump at the bottom of the collecting system of the oil or gas well. This inhibits corrosion in the metal work of the oil or gas well, for example the pipe lines of the collecting system.

Abstract: Compounds of formula I ##STR1## in which Ar is optionally substituted phenyl, R.sub.1 is an optionally substituted aliphatic group and R.sub.2 and R.sub.3 are H or optionally substituted alkyl groups or R.sub.2 and R.sub.3 together with the nitrogen atom to which they are attached complete a heterocyclic ring, are used in the treatment of Parkinson's disease. The compounds of formula I may be administered with a dopamine precursor such as levodopa and/or a dopa decarboxylase inhibitor such as carbidopa or benserazide. A preferred compound of formula I is N,N-dimethyl-1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamine hydrochloride monohydrate.

Abstract: Compounds of formula I ##STR1## in which R.sub.1 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, cycloalkylalkyl or optionally substituted phenyl; R.sub.2 is H or C.sub.1-3 alkyl; R.sub.3 and/or R.sub.4 are H, formyl, C.sub.1-3 alkyl, C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, C.sub.3-7 cycloalkyl or R.sub.3 and R.sub.4 together with the nitrogen atom form a heterocyclic ring system; R.sub.5 and/or R.sub.6 are H, halo, CF.sub.3, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, C.sub.1-3 alkylthio or R.sub.5 and R.sub.6 together with the carbon atoms to which they are attached form a second benzene ring show therapeutic activity in the treatment of depression. Pharmaceutical compositions and processes for preparing compounds of formula I are disclosed.

Abstract: Novel pharmaceutical powder and tablet compositions comprise ibuprofen or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable effervescent couple that produces carbon dioxide in the presence of water, a pharmaceutically acceptable surfactant and a pharmaceutically acceptable water-insoluble hydrophilic polymer. Preferred hydrophilic polymers are microcrystalline cellulose and croscarmellose sodium.Especially preferred are such compositions which have a saccharide dispersed therein. The incorporation of the saccharide, for example sucrose, lactose, dextrose or sorbitol, enhances the stability of the compositions.

Abstract: (1) Curable bisimide resins comprise a mixture of(a) 5 to 95% of at least one bisimide of the general formula I ##STR1## in which B represents a divalent radical containing a carbon-carbon double bond and A is a divalent radical containing at least two carbon atoms and(b) 95 to 5% of a polyhydantoin polymer of formula II ##STR2## wherein R.sub.1 represents an aromatic hydrocarbon radical, R.sub.2 represents hydrogen or an alkyl group having 1 to 6 carbon atoms, R.sub.3 represents an aromatic hydrocarbon radical, an alkyl radical having 4 to 10 carbon atoms optionally interrupted by one or more oxygen or sulphur atoms, and X is an integer of from 20 to 5000.

Abstract: Compounds of formula I ##STR1## in which R.sub.1 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, cycloalkylalkyl or optionally substituted phenyl; R.sub.2 is H or C.sub.1-3 alkyl; R.sub.3 and/or R.sub.4 are H, formyl, C.sub.1-3 alkyl, C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, C.sub.3-7 cycloalkyl or R.sub.3 and R.sub.4 together with the nitrogen atom form a heterocyclic ring system; R.sub.5 and/or R.sub.6 are H, halo, CF.sub.3, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, C.sub.1-3 alkylthio or R.sub.5 and R.sub.6 together with the carbon atoms to which they are attached form a second benzene ring show therapeutic activity in the treatment of depression. Pharmaceutical compositions and processes for preparing compounds of formula I are disclosed.

Abstract: A pharmaceutical composition comprising the analgesic and anti-inflammatory agent 2-(2-fluoro-4-biphenylyl)propionic acid or a pharmaceutically acceptable salt thereof and certain esters of natural vegetable oil fatty acids, provides a rapid release of 2-(2-fluoro-4-biphenylyl)propionic acid into the body, and hence a very rapid analgesic and anti-inflammatory effect.

Abstract: Quinolones with antihypertensive activity have the general formula I, ##STR1## wherein X is the residue of an optionally substituted benzene ring; R is lower alkyl; R.sub.3 is hydrogen or lower alkyl; R.sub.1 and R.sub.2, which may be the same or different, are hydrogen, lower alkyl, or, together with the nitrogen atom to which they are attached, form a 5 to 7 membered saturated heterocyclic ring optionally containing an additional hetero atom selected from nitrogen, oxygen and sulphur and optionally substituted by 1 or more lower alkyl groups; and the dotted line between positions 2 and 3 of the quinolone nucleus represents an optional bond. The compounds are useful as antihypertensive agents. They are also indicated for use in treating heart failure and ischaemic heart disease.

Abstract: Compounds of formula I ##STR1## in which R.sub.1 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, cycloalkylalkyl or optionally substituted phenyl; R.sub.2 is H or C.sub.1-3 alkyl; R.sub.3 and/or R.sub.4 are H, formyl, C.sub.1-3 alkyl, C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, C.sub.3-7 cycloalkyl or R.sub.3 and R.sub.4 together with the nitrogen atom form a heterocyclic ring system; R.sub.5 and/or R.sub.6 are H, halo, CF.sub.3, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, C.sub.1-3 alkylthio or R.sub.5 and R.sub.6 together with the carbon atoms to which they are attached form a second benzene ring show therapeutic acitivity in the treatment of depression. Pharmaceutical compositions and processes for preparing compounds of formula I are disclosed.

Abstract: Compounds of formula I ##STR1## in which R.sub.1 and R.sub.2, which may be the same or different, are hydrogen, a C.sub.1 to C.sub.3 alkyl group or R.sub.1 and R.sub.2 together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring; R.sub.3 and R.sub.4, which may be the same or different are hydrogen, a C.sub.1 to C.sub.3 alkyl or an optionally substituted C.sub.3 to C.sub.6 cycloalkyl group, or R.sub.3 and R.sub.4 together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring; m is 0, 1 or 2; p is 0, 1 or 2; E is an alkylene group connected to or interrupted by an oxygen or a sulphur atom; J is hydrogen or a substituent group; and their pharmaceutically acceptable salts have utility as histamine H.sub.2 -receptor antagonists.

Abstract: Compounds of formula I ##STR1## in which R.sub.1 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, cycloalkylalkyl or optionally substituted phenyl; R.sub.2 is H or C.sub.1-3 alkyl; R.sub.3 and/or R.sub.4 are H, formyl, C.sub.1-3 alkyl, C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, C.sub.3-7 cycloalkyl or R.sub.3 and R.sub.4 together with the nitrogen atom form a heterocyclic ring system; R.sub.5 and/or R.sub.6 are H, halo, CF.sub.3, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, C.sub.1-3 alkylthio or R.sub.5 and R.sub.6 together with the carbon atoms to which they are attached form a second benzene ring show therapeutic activity in the treatment of depression. Pharmaceutical compositions and processes for preparing compounds of formula I are disclosed.

Abstract: Curable resins comprising a mixture of(a) at least one bisimide of the general formula I ##STR1## in which B represents a divalent radical containing a carbon-carbon double bond and A is a divalent radical containing at least two carbon atoms,(b) at least one amino acid hydrazide of formula IIH.sub.2 N--D--CO--NHNH.sub.2 IIin which D is a divalent group, and(c) at least one alkenylphenol or ether thereof of formula IIIG--(E).sub.m --G IIIin which m=0 or 1, E is a divalent radical and G represents a phenyl ring substituted by at least one alkenyl group and at least one hydroxy or alkoxy group.

Abstract: Novel thienopyridones with antihypertensive activity have the formula I, ##STR1## wherein the ring A represents an optionally substituted thiophene ring; m is 0 or 1; n is 0, 1 or 2; R is lower alkyl and R.sub.1 is lower alkyl.The fused thieno-ring may carry one or two substituents.Formula I encompasses thieno[3,2-b]pyridones, thieno[3,4-b]pyridones and thieno[2,3-b]pyridones.Processes for preparing the novel thienopyridones and pharmaceutical compositions containing them are described. Pharmaceutically acceptable acid addition salts of the compounds of formula I are also described.The thienopyridones of formula I are antihypertensive agents and are also indicated for use in treating heart failure and ischaemic heart disease.

Abstract: Novel quinolones of formula I ##STR1## and pharmaceutically acceptable acid addition salts thereof in which the dotted line between positions 2 and 3 of the quinolone ring represents an optional bond, R is hydrogen, 1-methyl or 2-lower alkyl; R.sub.1 is lower alkyl; R.sub.2 is hydrogen, halo, lower alkyl, lower alkoxy, trifluoromethyl, cyano, difluoromethoxy, methylsulphinyl, phenylsulphinyl or the group --NR.sub.4 R.sub.5 or the N-oxide thereof wherein R.sub.4 and R.sub.5, which may be the same or different, are lower alkyl or, together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or morpholino radical; and R.sub.3 is hydrogen, fluoro, lower alkyl or lower alkoxy provided that, when R.sub.3 is lower alkoxy, R.sub.2 is other than lower alkoxy have utility as antihypertensive agents. Processes for preparing the quinolones and pharmaceutical compositions containing them are disclosed.

Abstract: A tablet for use in preserving samples of milk for analysis comprises bronopol (2-bromo-2-nitropropane-1,3-diol) and a water-soluble solid organic carboxylic acid, the amount of the organic acid being within the range 0.002-0.07 milli-equivalents per milligram of bronopol. The presence of the organic acid stabilizes the bronopol, thereby providing a tablet with an adequate shelf life. Suitable organic acids include citric acid, tartaric acid, malic acid, adipic acid, succinic acid and fumaric acid.

Abstract: Compounds of formula I ##STR1## in which n=0 or 1; in which, when n=0, R.sub.1 is H, an alkyl, a cycloalkyl, a cycloalkylmethyl, an alkenyl or, an alkynyl group a heterocyclic ring or an optionally substituted phenyl ring or when n=1, R.sub.1 is H or an alkyl group;in which R.sub.2 and R.sub.3 are H or an alkyl group;in which A is a group of formula III--(CH.sub.2).sub.x --W--(CH.sub.2).sub.y -- IIIin which W is an oxygen atom or a group of formula --S(O).sub.m --, a group of formula --CR.sub.12 R.sub.13 --, a cycloalkylidene group or a cycloalkylene group; x is 0 or an integer from 1 to 5; y is 0 or an integer from 1 to 5.in which R.sub.4 is a carbocyclic ring, a heterocyclic ring, a cyano group, a carbamoyl group, an alkoxycarbonyl group, an amido group, an acyloxy group, a hydroxy group, a thiol group, or a group of formula --OR.sub.20, --SR.sub.20, --SOR.sub.20 or SO.sub.2 R.sub.20.in which R.sub.5, R.sub.6 and R.sub.

Abstract: A container suitable for storing and dispensing parenteral fluids comprises a flat member 2 inserted into a pouch 1 of plastics material. The member has two ports 9, 10 passing therethrough which are protected by removeable tabs 14, 15 having passageways 19, 20 which are coaxial with the ports. The port 9 is sealed after filling by a cup-shaped closure (25, FIG. 4 not shown). The port 10 is closed by a ruptureable membrane and may have a resilient plug (29, FIG. 5 not shown) and needle guide (30, FIG. 5 not shown). The tabs may be connected to the member by portions 16, 16a, 17, 17a and 18 of reduced thickness. The outer ends of the passageways are sealed by covers 21, 22 or by flattening and sealing the ends of the passageways.The member, ports and tabs may be integrally formed by injection moulding (FIG. 1).

Abstract: Curable bisimide resin compositions containing 4,4'-bismaleimidodiphenylmethane, 1 to 20% of a compound of formula I ##STR1## and optionally 2 to 20% of a compound of formula II ##STR2## may be used in solution or as melts to produce fibre-reinforced resins.